Barrett, Amy
Olayinka-Amao, Oyebimpe
Ziemssen, Tjalf
Bharadia, Trishna
Henke, Christian
Kamudoni, Paul
Funding for this research was provided by:
Merck Healthcare KGaA
Article History
Received: 15 September 2023
Accepted: 17 January 2024
First Online: 12 February 2024
Declarations
:
: Amy Barrett and Oyebimpe Olayinka-Amao are employees of RTI Health Solutions. Tjalf Ziemssen reports consulting or serving on speaker bureaus for Biogen, Celgene, Roche, Novartis, Celgene, Merck Healthcare KGaA, Darmstadt, Germany, and Sanofi, as well as research support from Biogen, Novartis, Merck Healthcare KGaA, Darmstadt, Germany, and Sanofi. Trishna Bharadia has received honoraria and/or consulting fees from AbbVie, Becaris, King’s College London, Lumanity, Blue Latitude Health, Curatio, University College London, MS International Federation, Future Science Group, Savvy Cooperative, WEGO Health, Prime Global, Eyeforpharma, Professional Record Standards Body, DODS D&I, Queen Mary University London, Merck Healthcare KGaA, Darmstadt, Germany, The Method, Clara Health, The Conference Forum, Greenphire, Hollister, Medable, Oxford Health Policy Forum, College of Contemporary Health, Pfizer, Bristol Myers Squibb, UCB, Medidata, Talking Medicines, Pivot Digital, NHS England, Boeringher Ingelheim, MSD, Novartis, Parexel, Roche, Roche Information Solutions, Teva, and Sandoz. Christian Henke and Paul Kamudoni are employees of Merck Healthcare KGaA, Darmstadt, Germany.
: Ethical approvals were obtained from RTI’s Institutional Review Board (ID number 14206). The research was performed in accordance with the protocol, the provisions of the International Conference on Harmonisation, the Declaration of Helsinki, and applicable local regulatory requirements and laws.